Using Altmetrics to Highlight Academic Research: Innovative Possibilities

Rajiv Nariani, Science Librarian

York University

4:AM -- 27th Sep. 2017

The process….in a nutshell

- Run/Refine a PubMed affiliation search: YU & RU
  - Same search in Altmetric Explorer for Librarians
- Download the data in Excel: Refine:
  - Locate e-mail addresses
  - Add publication dates – Open Access or subscription
  - Include Google Scholar citations to all articles
- Plot AAS, News outlets, GS Citations in Tableau
- E-Mail Profs at YU & RU about the AAS and request to complete the online survey on Research Metrics
- Talk about possibilities…

yFile: Why only here?

Safe exercise guidelines for Type 1 Diabetes developed by international team led by York U researcher

January 24, 2017 | SHARE

An international team of researchers and clinicians led by York University Professor Michael Riddell has published a set of guidelines to help people with type 1 diabetes exercise safely to avoid fluctuations in blood sugar.

"Regular exercise can help individuals with diabetes to achieve their blood lipid, body composition, fitness and blood sugar goals, but for people living with type 1 diabetes, the fear of hypoglycemia, loss of glycemic control and inadequate knowledge around exercise management are major barriers," said Riddell, in the Faculty of Health. "This is a big struggle for both type 1 diabetes patients and their healthcare providers. This first ever set of consensus guidelines from leading experts will help them."

Patients with type 1 diabetes have to monitor their blood glucose levels before, during and after exercise, said Riddell, who led the team of 21 international experts. For two years, they reviewed observational studies and clinical trials on exercise management for people with type 1 diabetes who exercise regularly, to reach a consensus.

The guidelines on glucose targets for safe and effective exercising as well as nutritional and insulin dose adjustments to prevent exercise-related fluctuations in blood sugar, appear in the report, "Exercise management in type 1 diabetes: a consensus statement," published in *The Lancet Diabetes & Endocrinology*. This work was funded by the JDRF, a leading global organization funding type 1 diabetes research.

Michael Riddell

The authors note that a majority of people with type 1 diabetes are now overweight or obese and tend to be at least as inactive as the rest of the population. A large percentage of patients do not maintain a healthy body weight nor do they achieve the minimum required moderate-to-vigorous aerobic activity (150 minutes per week). This is in contrast to a few decades ago when most patients with the disease were relatively slim and active.

"Regular exercise helps patients achieve a number of goals. In pediatric patients, in particular, it reduces the cardiovascular

High AAS from YU March '17: G. Scholar Citations in Red
("york university"[Affiliation]) NOT ("new york"[Affiliation] OR "1new york"[Affiliation])

# 2016-15: Google Scholar/AAS/News Outlets

BAR COLOURS
- **Red: Subscription journal/Not OA**
- **Green: Open Access**
- **Blue: Open PMC**
- **Light Green: Open (YorkSpace)**
- **Purple : Open (Research Gate)**

2016-15: Hot Topics

Helping Connect with Faculty: Research Metrics

YORK
UNIVERSITÉ
UNIVERSITY

Were you aware: You are famous!!

York U.

Ryerson U.

York U.

ResearchGate

Twitter — 13
Facebook — 3
Mendeley — 0
My Google Scholar profile — 14
University web page/website — 16
I do not use any social media tools — 8
Other (please specify) — 10

Promoting my research……

- Ryerson Digital Repository
- LinkedIn

Twitter — 3
Facebook — 0
Mendeley — 0
My Google Scholar… — 5
University web… — 3
ResearchGate — 6
I do not use any… — 0
Other (please specify) — 2

Ryerson U.

YU: After knowing about AAS: Importance of statistics

How important are the following statistics [for your article(s)]

Bar chart showing importance ratings for various statistics:

mentions in F1000: N/A: 9, Not Imp.: 5, Imp.: 10, 2

Mentions in Wikipedia references: 4, Not Imp: 9, Imp: 11, Very Imp.: 5

Mentions in Policy documents: 1, Not Imp: 3, Imp.: 11, Very Imp: 18

Downloads by readers: 1, Not Imp: 2, Imp.: 12, Very Imp: 16

Mendeley readers & downloads: 3, Not Imp.: 12, Imp.: 12, 2

**Twitter mentions and posts**: 2, Not Imp.: 11, Imp: 17, 2

Facebook posts: 2, Not Imp: 14, Imp: 13, 2

Mentions in News Media: 0, Not Imp: 1, Imp: 18, Very Imp: 15

Total Citation count: 0, Not Imp: 0, Imp.: 11, Very Imp: 23

YU: What metrics do they want to know about


I would be interested in knowing more about these research impact metrics

YU: Altmetrics and Career Advancement

How important do you think are Altmetrics/alternative metrics for career advancement (One skipped)

Grant Applications
- N/A: 2
- Not Important 13
- Important 11
- Very Important 8

Tenure & Promotion
- N/A 4
- Not Important 13
- Important 10
- Very Important 7

I learned a lot - good luck with this research :)!

3/7/2017 11:50 AM   View respondent's answers   Categorize as... ▼

I am gratified that efforts are being made to develop this tool to quantify the impact of research. The h-index can be very misleading.

1/23/2017 6:05 PM   View respondent's answers   Categorize as... ▼

Interesting, important and contentious topic to explore...the landscape is changing quickly too which makes it hard for academics

1/10/2017 4:01 PM   View respondent's answers   Categorize as... ▼

i appreciate that the librarians teach us how us faculty can determine the impact of our work in these traditional and non-traditional ways

I like the idea, but it should be used carefully. Tweets and FB posts can be done by the general public without a scientific background and it can be amplified as a hype ("get viral") without real scientific relevance.

3/7/2017 1:00 PM   View respondent's answers   Categorize as... ▼

I wonder if something like altmetrics could serve as an alternative indicator of the interest and reach of my work to help sell a book proposal? Do you have any ideas about the kind of alternative metrics that could be assembled to help me in this regard. For example can altmetrics generate a score for a researcher not just an individual paper?

As you can see I don't really pay any attention to it. Sorry, I'm probably just too old!

12/27/2016 1:34 PM   View respondent's answers   Categorize as... ▼

They can be over-rated (over-inflated) and should be used with caution. Some scientists are better at "marketing/advertising" than others.

Creating a Canadian Research Impact Portal

Altmetrics Portal for Canadian Universities?

LSE & CSHL Repositories

Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines

Salas-Vega, Sebastian and Iliopoulos, Othon and Mossialos, Elias (2017) *Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines.* JAMA Oncology, 3 (3). pp. 382-390. ISSN 2374-2437

find a copy

PDF - Published Version
Restricted to Repository staff only until 29 December 2017.
Down...

- Author

Identification Nu...

Altmetric 717

Tweeted by **878**
On **12** Facebook pages
Mentioned in **6** Google+ posts
Picked up by **14** news outlets
Blogged by **1**

11 readers on Mendeley
0 readers on Connotea
0 readers on CiteULike

See more details
| Close this

Abstract

Importance: The ... newly licensed cancer medicines on therapy. This information could ... ion-making in the cancer drug market. Objective: To evaluate the ... ed by the US Food and Drug Administration (FDA) and the European ..., and Participants: We used a narrative synthesis approach to ... English, French, and Australian health technology assessments (HTAs) of all new cancer ... States and Europe between 2003 and 2013. Interventions: Sixty-two new molecular entities with a ... May 2015. Of these 53 drugs, 23 (43%) increased OS by 3 months or longer, 6 (11%) by less than 3 ... own magnitude; there was no evidence to suggest that the remaining 16 (30%) increased OS over best ... erall survival gains could be quantified, all new cancer drugs were associated with a mean (SE) total ... nths over the treatments that were available in 2003. Drug-related improvements in OS were, however, ... eutic targets—ranging between 0 (thyroid, ascites) and 8.48 months (breast cancers)—and were ... ata, indirect or nonactive comparisons, or nonvalidated evidence. Although 22 (42%) of 53 new ... an increase in QoL, 24 (45%) were also associated with reduced patient safety. Of the 53 new cancer ... d with at least some improvement in OS, QoL, or safety. Conclusions and Relevance: Although ... market has contributed to improvements in therapy, the magnitude and dimension of clinical benefits ... asons to doubt that claims of efficacy reflect real-world effectiveness exactly. These findings raise ... ecision-making and value-based policy.

/jamanetwork.com/journals/jamaoncology

17 American Medical Association

dicine > RA Public aspects of medicine
dicine > RM Therapeutics. Pharmacology

rtments > Social Policy
arch centres and groups > LSE Health and Social Care

r 2017 12:48

Oxidants, antioxidants and the current incurability of metastatic cancers

Watson, J. (2013) *Oxidants, antioxidants and the current incurability of metastatic cancers.* Open Biology, 3 (1). pp. 2046-2441.

PDF (Paper)
Watson Open Biology 2013.pdf - Published Version
Available under License Creative Commons Attribution.
Download (460Kb) | Preview

URL: http://www.ncbi.nlm.nih.gov/pubmed/23303309

DOI: 10.1098/rsob.120144

Abstract

The vast majority of all agents used to directly kill cancer cells (ionizing radiation, most chemotherapeutic agents and some targeted therapies) work through either directly or indirectly generating reactive oxygen species that block key steps in the cell cycle. As mesenchymal cancers evolve from their epithelial cell progenitors, they almost inevitably possess much-heightened amounts of antioxidants that effectively block otherwise highly effective oxidant therapies. Also key to better understanding is why and how the anti-diabetic drug metformin (the world's most prescribed pharmaceutical product) preferentially kills oxidant-deficient mesenchymal p53− –cells. A much faster timetable should be adopted towards developing more new drugs effective against p53− – cancers.

Item Type: Paper

Subjects: diseases & disorders > cancer
diseases & disorders
therapies
therapies > cancer drugs - see diseases-cancer-drugs and therapies

CSHL Authors:

Watson, James D.

Altmetric

590

YORK U
UNIVERSITÉ
UNIVERSITY

Browse

Search Term

Protocol Of A Randomized Controlled Trial Of The Fear Of Recurrence Therapy (FORT) Intervention For Women With Breast Or Gynecological Cancer

Browse » Research » Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer

Details

Date	2016-04-25T00:00:00Z
Contributor	Maheu, Christine (Author)
	Lebel, Sophie (Author)
	Courbasson, Christine (Author)
	Lefebvre, Monique (Author)
	Singh, Mina (Author)
	Bernstein, Lori J. (Author)
	Muraca, Linda (Author)
	Benea, Aronela (Author)

BioMed Central

Login

BMC Cancer

HOME   ABOUT   ARTICLES   SUBMISSION GUIDELINES

Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer

Christine Maheu ✉ , Sophie Lebel, Christine Courbasson, Monique Lefebvre, Mina Singh, Lori J. Bernstein, Linda Muraca, Aronela Benea, Lynne Jolicoeur, Cheryl Harris, Agnihotram V. Ramanakumar, Sarah Ferguson and Souraya Sidani

Open Peer Review reports

Download PDF

Export citations

Can basic AAS data show up in Web of Science? For institutions subscribing to WoS?

In our Teaching & Learning….

Altmetrics: Making Inroads

- Collection Development & research landscape
- Discussing metrics with faculty and graduate students
- Altmetrics in Institutional Repositories
- Altmetric: University Research Office & Media Communications
- Altmetric: Scholars Portal & OCUL
- Altmetric: Funding Agencies

YORK U
UNIVERSITÉ
UNIVERSITY